Sun Pharma Agrees to $11.8 Billion Acquisition of Organon
India’s Sun Pharmaceutical Industries has agreed to acquire U.S.-listed Organon for $11.75 billion in an all-cash deal, leading to a 15% surge in Organon’s shares. The acquisition aims to expand Sun Pharma’s global presence and strengthen its portfolio in branded generics, innovative therapies, and biosimilars.
Topics: mergers and acquisitions pharmaceutical industry stock price movement strategic expansion